
Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).
Vykat XR, a modified tablet version of a 50-year-old generic suspension, carries an annual cost of $500,000, the report claims.